Pharma Stocks
-
Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data
Ascendis Pharma (NasdaqGS:ASND) is back in focus after new Week 104 radiographic data from its pivotal ApproaCH trial of once…
Read More » -
Merck KGaA (XTRA:MRK) Expands Into Precision Cardiology, Is The Upside Already Priced In?
Merck KGaA (XTRA:MRK) has moved deeper into precision cardiology, committing a $50 million upfront payment and a build-to-buy structure with…
Read More » -
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driven disruptors.…
Read More » -
Dr. Reddy’s Lab jumps 2%: Why is this pharma stock rising?
Shares of Dr. Reddy’s Laboratories climbed nearly 2% on the NSE on Thursday after the pharmaceutical major announced an expansion…
Read More » -
Has Island Pharmaceuticals (ASX:ILA) More Growth Ahead After a 164% One-Year Rally?
Highlights • Island Pharmaceuticals shares have risen more than 164% over the past year. • The company’s antiviral drug development…
Read More » -
Wall Street Thinks This Biotech Stock Can Soar 45%. Here’s Why Analysts Are Right.
Shares of Alnylam Pharmaceuticals (ALNY +3.69%) have dropped 24% so far this year (through June 30). The biotech company is…
Read More » -
Wall Street Thinks This Biotech Stock Can Soar 45%. Here’s Why Analysts Are Right.
Key Points The company has six marketed therapies and several others in late-stage clinical trials. Alnylam has a unique drug…
Read More » -
Neuren Pharmaceuticals (ASX:NEU) Wins CHMP Backing, Is The Upside Already Priced In?
Neuren Pharmaceuticals (ASX:NEU) is back in focus after the European Medicines Agency’s CHMP issued a positive opinion on its Rett…
Read More » -
Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update
Highlights • Telix Pharmaceuticals shares rose 0.41% to AUD 17.09 during the morning session on 2 July 2026 following a…
Read More » -
How Teva’s Ecopipam NDA for Pediatric Tourette Syndrome (TEVA) Has Changed Its Investment Story
In June 2026, Teva Pharmaceutical Industries announced it had submitted a New Drug Application to the FDA for ecopipam, a…
Read More »